6GZM
Crystal Structure of Human CKIdelta with A86
6GZM の概要
エントリーDOI | 10.2210/pdb6gzm/pdb |
分子名称 | Casein kinase I isoform delta, CITRIC ACID, GLYCEROL, ... (5 entities in total) |
機能のキーワード | cdk9, kinase inhibitor, a86, transferase |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 69872.60 |
構造登録者 | Ben-neriah, Y.,Venkatachalam, A.,Minzel, W.,Fink, A.,Snir-Alkalay, I.,Vacca, J. (登録日: 2018-07-04, 公開日: 2018-08-29, 最終更新日: 2024-01-17) |
主引用文献 | Minzel, W.,Venkatachalam, A.,Fink, A.,Hung, E.,Brachya, G.,Burstain, I.,Shaham, M.,Rivlin, A.,Omer, I.,Zinger, A.,Elias, S.,Winter, E.,Erdman, P.E.,Sullivan, R.W.,Fung, L.,Mercurio, F.,Li, D.,Vacca, J.,Kaushansky, N.,Shlush, L.,Oren, M.,Levine, R.,Pikarsky, E.,Snir-Alkalay, I.,Ben-Neriah, Y. Small Molecules Co-targeting CKI alpha and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell, 175:171-185.e25, 2018 Cited by PubMed Abstract: CKIα ablation induces p53 activation, and CKIα degradation underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome. Here we describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 and CDK9, thereby augmenting CKIα-induced p53 activation and its anti-leukemic activity. Oncogene-driving super-enhancers (SEs) are highly sensitive to CDK7/9 inhibition. We identified multiple newly gained SEs in primary mouse acute myeloid leukemia (AML) cells and demonstrate that the inhibitors abolish many SEs and preferentially suppress the transcription elongation of SE-driven oncogenes. We show that blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, and induce apoptosis. Leukemia progenitors are selectively eliminated by the inhibitors, explaining their therapeutic efficacy with preserved hematopoiesis and leukemia cure potential; they eradicate leukemia in MLL-AF9 and Tet2;Flt3 AML mouse models and in several patient-derived AML xenograft models, supporting their potential efficacy in curing human leukemia. PubMed: 30146162DOI: 10.1016/j.cell.2018.07.045 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.59 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード